This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Flamel Technologies

Drug Names(s): long-acting basal insulin

Description: FT-105 is a long-acting recombinant insulin formulation that uses a microparticulate adaptation of Flamel’s proprietary Medusa nanoparticle delivery system. FT-105 comprises lyophilised microparticles of Medusa nanopolymers embedded with recombinant human insulin.

FT-105 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug